Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: Implications for clinical translation

by McMillin D.W., Delmore J., Negri J., Ooi M., Klippel S., Miduturu C.V., Gray N.S., Richardson P.G., Anderson K.C., Kung A.L., Mitsiades C.S.
Published 2019

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival

by Ohguchi, H, Hideshima, T, Bhasin, M.K, Gorgun, G.T, Santo, L, Cea, M, Samur, M.K, Mimura, N, Suzuki, R, Tai, Y.-T, Carrasco, R.D, Raje, N, Richardson, P.G, Munshi, N.C, Harigae, H, Sanda, T, Sakai, J, Anderson, K.C
Published 2020

Management of treatment-emergent peripheral neuropathy in multiple myeloma

by Richardson, P.G., Delforge, M., Beksac, M., Wen, P., Jongen, J.L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S.V., Harousseau, J.L., Moreau, P., Avet-Loiseau, H., Lee, J.H., Cavo, M., Merlini, G., Voorhees, P., Chng, W.J., Mazumder, A., Usmani, S., Einsele, H., Comenzo, R., Orlowski, R., Vesole, D., Lahuerta, J.J., Niesvizky, R., Siegel, D., Mateos, M.-V., Dimopoulos, M., Lonial, S., Jagannath, S., Bladé, J., Miguel, J.S., Morgan, G., Anderson, K.C., Durie, B.G.M., Sonneveld, P.
Published 2016